Stay updated with breaking news from Nasdaq Tkno. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Alpha Teknova (NASDAQ:TKNO – Get Rating) is one of 39 public companies in the “Diagnostic substances” industry, but how does it compare to its peers? We will compare Alpha Teknova to related companies based on the strength of its dividends, risk, profitability, institutional ownership, valuation, earnings and analyst recommendations. Insider and Institutional Ownership 25.5% of […]
Alpha Teknova (NASDAQ:TKNO – Get Rating) is one of 39 publicly-traded companies in the “Diagnostic substances” industry, but how does it contrast to its rivals? We will compare Alpha Teknova to similar companies based on the strength of its risk, earnings, analyst recommendations, profitability, institutional ownership, dividends and valuation. Analyst Recommendations This is a breakdown […]
Alpha Teknova (NASDAQ:TKNO – Get Rating) is one of 39 public companies in the “Diagnostic substances” industry, but how does it compare to its rivals? We will compare Alpha Teknova to related businesses based on the strength of its dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership. Insider and Institutional Ownership 25.5% of […]
Alpha Teknova (NASDAQ:TKNO – Get Rating) is one of 39 public companies in the “Diagnostic substances” industry, but how does it contrast to its competitors? We will compare Alpha Teknova to similar businesses based on the strength of its institutional ownership, dividends, profitability, analyst recommendations, valuation, risk and earnings. Profitability This table compares Alpha Teknova […]
Alpha Teknova (NASDAQ:TKNO – Get Rating) is one of 39 publicly-traded companies in the “Diagnostic substances” industry, but how does it contrast to its competitors? We will compare Alpha Teknova to related businesses based on the strength of its earnings, profitability, institutional ownership, dividends, risk, valuation and analyst recommendations. Institutional & Insider Ownership 25.5% of […]